Syndax Pharmaceuticals is set for significant growth driven by its drugs Revuforj and Niktimvo, with management projecting over $2 billion in peak U.S. sales for Revuforj. Recent trial data for Revuforj in acute myeloid leukemia (AML) show an 88% overall response rate and strong minimal residual disease negativity, supporting ongoing phase 3 trials and expanding real-world use. The company's pipeline includes next-generation menin and EGFR inhibitors targeting diseases like myelofibrosis and non-small cell lung cancer, with rapid proof-of-concept timelines. While risks remain from upcoming clinical readouts and competition, Syndax offers a compelling long-term investment opportunity, especially for risk-tolerant investors.
Syndax Pharmaceuticals is the subject of this update, presented here with relevant market data from Pluang's health sector as of Sep 25, 2026 22:01 WIB. Among 100 priced health-sector US stocks, 43 advanced while 55 declined. Notably, BioNano Genomics Inc (BNGO) traded at USD 1.66 with a 1-day change of -1.78% and a strong buy order activity of 87%, contrasting with 10X Genomics Inc (TXG) at USD 82.64, down 1.75%, and Crispr Therapeutics AG (CRSP) at USD 54.74, down 1.72% but with 100% buy orders. Typical hold times ranged from 49 to 94 days, illustrating varied investor engagement across these assets.
Ivanhoe Electric's Santa Cruz Copper Mining Project in Arizona has strong economic potential, according to a recent Preliminary Feasibility Study. The project requires $1.43 billion in initial capital and expects low operating costs of $1.47 per poun...
The Ninepoint North American Energy Independence ETF (ENRG) launched amid volatile crude prices, aiming to capitalize on U.S. and Canadian energy interdependence. Its success depends on two key unknowns: the fund's exact holdings mix between oil, gas...
The Vanguard Morningstar Large Cap ETF (VV) provides broad exposure to large U.S. companies but is heavily concentrated in technology and mega-cap stocks, with its top 10 holdings making up 38.1% of assets. Notably, Nvidia, Apple, and Microsoft alone...
Conagra Brands has reduced its dividend payout by 50% to accelerate deleveraging and manage ongoing margin pressures caused by inflation and competitive challenges. This move reflects concerns about the sustainability of previous dividend levels desp...
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) received a reiterated 'sell' rating because its long-term return prospects are inferior compared to peers. Its strict 25-year dividend growth requirement leads to sector imbalances, overweighting ...
